Key Takeaways
A class-action lawsuit was filed against Corcept Therapeutics Inc. (NASDAQ: CORT) after its stock lost more than half its value following the rejection of a key drug by the U.S. Food and Drug Administration.
The lawsuit, filed by firms including Bronstein, Gewirtz & Grossman, alleges Corcept misled investors about the approval prospects for its drug relacorilant. "Defendants’ Class Period representations that the relacorilant NDA was supported by powerful evidence... were false," according to the complaint filed by Kaplan Fox & Kilsheimer.
The legal action covers investors who purchased Corcept stock between October 31, 2024, and December 30, 2025. The truth emerged on December 31, 2025, when Corcept disclosed the FDA had issued a Complete Response Letter for the relacorilant New Drug Application, stating it could not approve the drug without additional evidence.
Following the announcement, Corcept's stock price collapsed by $35.40 per share, a 50.4 percent decline, wiping out significant shareholder value. The company's CEO, Joseph Belanoff, was quoted in a press release as being "surprised and disappointed by this outcome." Law firms are now seeking to recover damages for investors, with an April 21, 2026 deadline to serve as lead plaintiff.
The lawsuit alleges that throughout the Class Period, the company was aware of FDA concerns regarding the adequacy of clinical evidence for relacorilant, a candidate for treating hypercortisolism, also known as Cushing's syndrome. This contrasts with the company's public statements, which expressed confidence in the NDA and suggested approval was approaching.
The sharp stock decline reflects the market's adjustment to the new reality of a significant delay, if not outright failure, for Corcept's lead product candidate. The legal proceedings will now add another layer of uncertainty for the pharmaceutical company.
The stock's precipitous fall has brought it to its lowest point since 2024, creating a significant technical challenge for any potential recovery. Investors will be closely watching for the company's official response to the lawsuit and any updates on its plan to gather the additional evidence required by the FDA.
This article is for informational purposes only and does not constitute investment advice.
